Rajarashi Guha Selected Research

Rhabdomyosarcoma

1/2018	MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma.
1/2018	Functional screening of FGFR4-driven tumorigenesis identifies PI3K/mTOR inhibition as a therapeutic strategy in rhabdomyosarcoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Rajarashi Guha Research Topics

Disease

2	Rhabdomyosarcoma 01/2018 - 01/2018
2	Neoplasms (Cancer) 01/2018 - 01/2018
1	Sarcoma (Soft Tissue Sarcoma) 01/2018

Drug/Important Bio-Agent (IBA)

1	MTOR InhibitorsIBA 01/2018
1	Transcription Factors (Transcription Factor)IBA 01/2018
1	Protein Isoforms (Isoforms)IBA 01/2018
1	Mitogen-Activated Protein KinasesIBA 01/2018
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2018
1	trametinibIBA 01/2018
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 01/2018
1	omipalisibIBA 01/2018

Therapy/Procedure

1	Therapeutics 01/2018